Skip to content
Screener

Viridian Therapeutics, Inc. VRDN Gross margin

Discontinued — last reported Q3 '16

Gross margin at other companies

Amgen logo
AmgenAMGN
69.5%+5.0pp
Regenxbio logo
RegenxbioRGNX
59.7%+1.0pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
95.5%+23.5pp
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
97.8%+0.8pp
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
90.4%+0.8pp
Moderna logo
ModernaMRNA
23.4%-29.1pp

Other financials

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.55B+81.7%
Enterprise value$2.5B+90.9%
P/S35.9×-4,565×

Profitability

See full
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Calculated from Viridian Therapeutics, Inc.’s reported figures.

gross profit/total revenue=36.3%

Based on trailing twelve months.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed November 9, 2017. Open the filing →

Filed
Nov 8, 2017, 6:00 PM EST
Fiscal quarter
Q3 FY2017
Calendar quarter
Q3 2017
Accession
0001590750-17-000010

FAQ

What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.